Answers are grounded in this paper and cite their sources.
Background Late-life depression with inadequate antidepressant response is a pressing clinical issue with limited proven therapies. Nitrous oxide (N 2 O) may offer a new therapeutic avenue with rapid and safe antidepressant effects in late-life depression with inadequate antidepressant response. Methods We conducted a double-blind, randomised, placebo-controlled, single-dose trial (November 2021–December 2024) in three old-age psychiatry departments at French university hospitals. Eligible participants were aged 60–90 years with a current major depressive episode, a Montgomery-Åsberg Depression Rating Scale (MADRS) score >20 and documented non-response to ≥1 adequate antidepressant trial. Participants were randomly assigned (1:1) to a single 60-min inhalation of either 50% N 2 O/50% O 2 (N 2 O group) or medical air (placebo group). The primary outcome was change in MADRS score from baseline to 2 weeks, analysed under the intention-to-treat principle with a linear mixed-effects model using all available data. Secondary outcomes included clinician- and self-rated depressive symptom scales and safety. The study is complete and registered in ClinicalTrials.gov (NCT05007028). Findings Among the 60 participants enrolled in the study, those who received N 2 O experienced a significant and sustained reduction in depressive symptoms compared to the placebo group. The antidepressant effect was rapid, with significant improvements noted as early as 24 h and at one week. At the two-week endpoint, the N2O group showed a significantly greater reduction in MADRS scores (−6.2 points; 95% CI: −9.1 to −3.4; P < 0.001). These positive findings were supported by both clinician- and self-rated questionnaires, and all reported adverse events were mild and transient. Interpretation While further studies are needed to confirm its long-term efficacy and safety, our findings suggest that N 2 O offers a new therapeutic strategy with rapid, sustained and safe antidepressant effects in late-life depression with inadequate antidepressant response. Funding This study was supported by a grant from the French Ministry of Health and Prevention.
No takes yet. Share an insight, caveat, or question.
Salamé et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: